RTI Health Solutions[®]

Identification of Migraine in Electronic Healthcare Data Sources

A HEADACHE FOR PHARMACOEPIDEMIOLOGISTS A Systematic Literature Review

Joan Forns, MPH, PhD; Alicia Abellan, MPH, PhD; Nuria Riera, PharmD, PhD; Andrea Margulis, MD, ScD, FISPE; Elena Rivero-Ferrer, MD, MPH, FISPE Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain

Disclosures: JF, AA, NR, AM, and ER are full-time employees of RTI Health Solutions, a unit of RTI International, a nonprofit organisation that conducts work for government, public, and private organisations, including pharmaceutical companies.

- Ascertaining migraine in electronic healthcare data is challenging
- Migraine prevalence will depend on the characteristics of the migraine-identifying strategy and data source

Objective

To describe migraineidentifying algorithms implemented in observational studies using healthcare administrative claims, electronic medical records, or other data sources and any related validation efforts; and to summarise the prevalence of migraine reported in each study



Results

- 16 studies used only diagnosis codes.
- Most common: ICD-9 346.xx or ICD-10 G43.xx.
- Prevalence of migraine (unspecified whether acute or chronic) range: 4.0% to 4.8%.

Methods

Identification

Eligibility


2

Articles identified in PubMed (2013-2023) N = 360

Articles excluded at Level 1 = 310 Level 2 Screen [Full text screened]

N = 50

- 5 studies used only migraine treatments.
- Most common: triptans (ATC: N02CC), followed by ergotamines. Only 1 study used prophylactic drugs.
- 3 studies required only 1 prescription, whilst 2 studies required > 1 prescription.
- No prevalence reported.
- 9 studies used a combination of diagnosis codes and/or treatments.
- Most common: a single diagnosis code (ICD-9 346.xx or ICD-10 G43.xx) or a treatment code (mostly triptans).
- Prevalence of migraine range: 7.7% (acute migraine) to 17% (acute or chronic migraine).



- 11 studies used a combination of diagnosis codes, treatments, and settings.
- 2 studies reported validation results (PPVs ranging between 68% and 97%), depending on the diagnostic threshold and the gold standard used.
- 2 studies reported acute migraine prevalences of 4% to 5% (up to 11.9% using a broader definition); 1 study reported chronic migraine prevalence as < 1%.

CONCLUSION

Most studies included in this systematic review identified migraine using diagnosis codes. Only studies that included a combination of diagnosis codes and treatments in different settings identified specific migraine types and reported results on validation.

Presented at: 2024 ISPE Annual Meeting; 24-28 August 2024; Berlin, Germany

Contact: Joan Forns, MPH, PhD | RTI Health Solutions | Av. Diagonal 605, 9-1 08028, Barcelona, Spain | Email: jforns@rti.org